JNJ Stock Recent News
JNJ LATEST HEADLINES
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
In the most recent trading session, Johnson & Johnson (JNJ) closed at $158.68, indicating a +0.52% shift from the previous trading day.
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The U.S. Food and Drug Administration has approved a bi-weekly dose of the blood cancer therapy Tecvayli, Johnson & Johnson said on Tuesday.
Johnson & Johnson has an incredible streak of annual dividend raises. Apple's booming services segment and vast ecosystem are the future of the business.
Alvotech said on Thursday it has reached settlement agreements with Johnson & Johnson for launching the biosimilar of the pharmaceutical giant's blockbuster psoriasis drug Stelara in Japan, Canada and the European Economic Area.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at the Loews Miami Beach Hotel, Miami Beach, FL. Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision will represent the Company in a session scheduled at 10:45 a.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson websit.
The Dow Jones Industrial Average has been Wall Street's health barometer since the late 1800s. The Dow comprises 30 time-tested, multinational businesses, which means it's a great place for investors to search for amazing deals.
Johnson & Johnson focuses on pharmaceuticals and medical devices after spinning off its consumer-health segment. The company's solid pipeline of cancer, immunology, and neurology drugs, along with its leading medical device portfolio, offer growth prospects. Johnson & Johnson reported strong Q4 earnings, beating revenue forecasts, and expects continued growth in pharmaceutical sales and revenue in FY24.
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.